Nurix Therapeutics, Inc. (NRIX) NASDAQ
17.56
+0.0637(+0.36%)
Currency In USD
- General
- Statistics
- Historical Data
- Profile
- Financials
17.56
+0.0637(+0.36%)
Currency In USD
| Previous Close | 17.5 |
| Open | 17.55 |
| Day High | 17.82 |
| Day Low | 17.27 |
| 52-Week High | 22.5 |
| 52-Week Low | 8.2 |
| Volume | 303,906.48 |
| Average Volume | 1.13M |
| Market Cap | 1.52B |
| PE | -5.54 |
| EPS | -3.17 |
| Moving Average 50 Days | 16.05 |
| Moving Average 200 Days | 14.47 |
| Change | 0.06 |
Nurix Therapeutics Outlines 2026 Goals and Objectives for Advancing Bexobrutideg and Its Pipeline of Novel Degrader-Based Medicines in Cancer and Autoimmune Diseases
GlobeNewswire Inc.
Jan 12, 2026 12:00 PM GMT
Execute a pivotal program for potential best-in-class BTK degrader, bexobrutideg, including Phase 2 and confirmatory Phase 3 studies to support global registration in relapsed/refractory chronic lymphocytic leukemia (r/r CLL) Expand bexobrutideg into
Nurix Therapeutics to Participate in the 44th Annual J.P. Morgan Healthcare Conference
GlobeNewswire Inc.
Jan 05, 2026 12:00 PM GMT
BRISBANE, Calif., Jan. 05, 2026 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted protein degradation medicines in oncolog
Nurix Therapeutics Presents New Data from the Phase 1 Trial of Bexobrutideg (NX-5948) in Waldenström Macroglobulinemia at the 67th American Society of Hematology (ASH) Annual Meeting and Exposition
GlobeNewswire Inc.
Dec 08, 2025 1:00 PM GMT
Objective response rate (ORR) of 75.0% including three very good partial responses (VGPR) in heavily pre-treated Waldenström macroglobulinemia patients With a median follow up of 8.1 months, median duration of response (DOR) and median progression-fr